Share-based Payment Arrangement, Expense of TANDEM DIABETES CARE INC from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
TANDEM DIABETES CARE INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • TANDEM DIABETES CARE INC Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $20,108,000, a 29% decline year-over-year.
  • TANDEM DIABETES CARE INC Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $92,381,000, a 8.9% decline year-over-year.
  • TANDEM DIABETES CARE INC annual Share-based Payment Arrangement, Expense for 2025 was $92,381,000, a 8.9% decline from 2024.
  • TANDEM DIABETES CARE INC annual Share-based Payment Arrangement, Expense for 2024 was $101,383,000, a 15% increase from 2023.
  • TANDEM DIABETES CARE INC annual Share-based Payment Arrangement, Expense for 2023 was $88,076,000, a 3.7% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

TANDEM DIABETES CARE INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $92,381,000 $20,108,000 -$8,058,000 -29% 01 Oct 2025 31 Dec 2025 10-K 19 Feb 2026 2025 FY
Q3 2025 $100,439,000 $21,142,000 -$5,139,000 -20% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $105,578,000 $25,642,000 +$745,000 +3% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $104,833,000 $25,489,000 +$3,450,000 +16% 01 Jan 2025 31 Mar 2025 10-Q 30 Apr 2025 2025 Q1
Q4 2024 $101,383,000 $28,166,000 +$5,426,000 +24% 01 Oct 2024 31 Dec 2024 10-K 19 Feb 2026 2025 FY
Q3 2024 $95,957,000 $26,281,000 +$5,540,000 +27% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $90,417,000 $24,897,000 +$1,496,000 +6.4% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $88,921,000 $22,039,000 +$845,000 +4% 01 Jan 2024 31 Mar 2024 10-Q 30 Apr 2025 2025 Q1
Q4 2023 $88,076,000 $22,740,000 -$1,702,000 -7% 01 Oct 2023 31 Dec 2023 10-K 19 Feb 2026 2025 FY
Q3 2023 $89,778,000 $20,741,000 -$1,495,000 -6.7% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $91,273,000 $23,401,000 +$3,271,000 +16% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $88,002,000 $21,194,000 +$3,084,000 +17% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $84,918,000 $24,442,000 +$7,343,000 +43% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $77,575,000 $22,236,000 +$6,507,000 +41% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $71,068,000 $20,130,000 +$5,153,000 +34% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $65,915,000 $18,110,000 +$5,163,000 +40% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $60,752,000 $17,099,000 +$3,791,000 +28% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
Q3 2021 $56,961,000 $15,729,000 +$2,892,000 +23% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $54,069,000 $14,977,000 -$1,444,000 -8.8% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $55,513,000 $12,947,000 -$2,918,000 -18% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $58,431,000 $13,308,000 -$5,286,000 -28% 01 Oct 2020 31 Dec 2020 10-K 22 Feb 2023 2022 FY
Q3 2020 $63,717,000 $12,837,000 -$4,393,000 -25% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $68,110,000 $16,421,000 +$4,008,000 +32% 01 Apr 2020 30 Jun 2020 10-Q 04 Aug 2021 2021 Q2
Q1 2020 $64,102,000 $15,865,000 +$6,031,000 +61% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $58,071,000 $18,594,000 +$8,285,000 +80% 01 Oct 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
Q3 2019 $49,786,000 $17,230,000 +$7,693,000 +81% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $42,093,000 $12,413,000 +$9,715,000 +360% 01 Apr 2019 30 Jun 2019 10-Q 30 Jul 2020 2020 Q2
Q1 2019 $32,378,000 $9,834,000 +$8,642,000 +725% 01 Jan 2019 31 Mar 2019 10-Q 30 Apr 2020 2019 Q1
Q4 2018 $23,736,000 $10,309,000 +$8,183,000 +385% 01 Oct 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
Q3 2018 $15,553,000 $9,537,000 +$7,145,000 +299% 01 Jul 2018 30 Sep 2018 10-Q 04 Nov 2019 2019 Q3
Q2 2018 $8,408,000 $2,698,000 -$2,448,000 -48% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $10,856,000 $1,192,000 -$1,772,000 -60% 01 Jan 2018 31 Mar 2018 10-Q 30 Apr 2019 2019 Q1
Q4 2017 $12,628,000 $2,126,000 -$800,000 -27% 01 Oct 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
Q3 2017 $13,428,000 $2,392,000 -$513,000 -18% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $13,941,000 $5,146,000 +$2,117,000 +70% 01 Apr 2017 30 Jun 2017 10-Q 30 Jul 2018 2018 Q2
Q1 2017 $11,824,000 $2,964,000 +$164,000 +5.9% 01 Jan 2017 31 Mar 2017 10-Q 26 Apr 2018 2018 Q1
Q4 2016 $11,660,000 $2,926,000 -$160,000 -5.2% 01 Oct 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 $11,820,000 $2,905,000 -$72,000 -2.4% 01 Jul 2016 30 Sep 2016 10-Q 26 Oct 2017 2017 Q3
Q2 2016 $11,892,000 $3,029,000 -$231,000 -7.1% 01 Apr 2016 30 Jun 2016 10-Q 27 Jul 2017 2017 Q2
Q1 2016 $12,123,000 $2,800,000 -$973,000 -26% 01 Jan 2016 31 Mar 2016 10-Q 27 Apr 2017 2017 Q1
Q4 2015 $13,096,000 $3,086,000 -$861,000 -22% 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
Q3 2015 $13,957,000 $2,977,000 -$769,000 -21% 01 Jul 2015 30 Sep 2015 10-Q 01 Nov 2016 2016 Q3
Q2 2015 $14,726,000 $3,260,000 -$271,000 -7.7% 01 Apr 2015 30 Jun 2015 10-Q 28 Jul 2016 2016 Q2
Q1 2015 $14,997,000 $3,773,000 +$2,000 +0.05% 01 Jan 2015 31 Mar 2015 10-Q 28 Apr 2016 2016 Q1
Q4 2014 $14,995,000 $3,947,000 01 Oct 2014 31 Dec 2014 10-K 08 Mar 2017 2016 FY
Q3 2014 $3,746,000 01 Jul 2014 30 Sep 2014 10-Q 29 Oct 2015 2015 Q3
Q2 2014 $3,531,000 +$2,943,000 +501% 01 Apr 2014 30 Jun 2014 10-Q 30 Jul 2015 2015 Q2
Q1 2014 $3,771,000 +$3,715,000 +6634% 01 Jan 2014 31 Mar 2014 10-Q 30 Apr 2015 2015 Q1
Q2 2013 $588,000 01 Apr 2013 30 Jun 2013 10-Q 31 Jul 2014 2014 Q2
Q1 2013 $56,000 01 Jan 2013 31 Mar 2013 10-Q 06 May 2014 2014 Q1

TANDEM DIABETES CARE INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $92,381,000 -$9,002,000 -8.9% 01 Jan 2025 31 Dec 2025 10-K 19 Feb 2026 2025 FY
2024 $101,383,000 +$13,307,000 +15% 01 Jan 2024 31 Dec 2024 10-K 19 Feb 2026 2025 FY
2023 $88,076,000 +$3,158,000 +3.7% 01 Jan 2023 31 Dec 2023 10-K 19 Feb 2026 2025 FY
2022 $84,918,000 +$24,166,000 +40% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $60,752,000 +$2,321,000 +4% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $58,431,000 +$360,000 +0.62% 01 Jan 2020 31 Dec 2020 10-K 22 Feb 2023 2022 FY
2019 $58,071,000 +$34,335,000 +145% 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
2018 $23,736,000 +$11,108,000 +88% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $12,628,000 +$968,000 +8.3% 01 Jan 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
2016 $11,660,000 -$1,436,000 -11% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
2015 $13,096,000 -$1,899,000 -13% 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
2014 $14,995,000 +$10,539,000 +237% 01 Jan 2014 31 Dec 2014 10-K 08 Mar 2017 2016 FY
2013 $4,456,000 +$4,210,000 +1711% 01 Jan 2013 31 Dec 2013 10-K 24 Feb 2016 2015 FY
2012 $246,000 01 Jan 2012 31 Dec 2012 10-K 24 Feb 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.